Back to search results

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer · Hormone Receptor-positive Breast Cancer · Hormone Therapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

    Contact: Study coordinator (Yen-Shen Lu, MD, PhD) · yslu@ntu.edu.tw · 886-2-23123456
    Contact: Principal Investigator (Yen-Shen Lu, MD, PhD)
    Ching-Hung Lin, MD, PhD (Sub-investigator)
    Dwan-Ying Chang, MD (Sub-investigator)
    Tom Wei-Wu Chen, MD, PhD (Sub-investigator)
    I-Chun Chen, MD, PhD (Sub-investigator)
    Wei-Li Ma, MD (Sub-investigator)
    Ming-Yang Wang, MD, PhD (Sub-investigator)

  • Department of Oncology,National Taiwan University Hospital, Taipei, Taiwan

    Contact: Study coordinator (Yen-Shen Lu, M.D.,Ph.D) · yslu@ntu.edu.tw · 886-2-23123456
    Contact: Study coordinator (I-Chun Chen, M.D.,Ph.D) · A00523@ntucc.gov.tw · 886-2-23123456
    Ching-Hung Lin, M.D.,Ph.D (Sub-investigator)
    Dwan-Ying Chang, M.D. (Sub-investigator)
    Tom Wei-Wu Chen, M.D.,Ph.D (Sub-investigator)
    I-Chun Chen, M.D.,Ph.D (Sub-investigator)
    Ming-Yang Wang, M.D.,Ph.D (Sub-investigator)
    Wei-Li Ma, M.D. (Sub-investigator)
    Contact: Principal Investigator (Yen-Shen Lu, M.D.,Ph.D)
Study leads

  • Yen-Shen Lu, MD, PhD

    Principal Investigator

    National Taiwan University Hospital

View source on ClinicalTrials.gov(opens in a new tab)